[Rapid health technology assessment of oral Chinese patent medicines for inflammatory bowel disease].

This paper systematically evaluated the efficacy, safety, and economic profile of oral Chinese patent medicine for the treatment of inflammatory bowel disease(IBD) through rapid health technology assessment. A total of 145 studies(including 110 RCTs) were included, involving 23 kinds of Chinese patent medicines. The results demonstrate that most Chinese patent medicines, used alone or combined with western medicine, exhibit superior outcomes in terms of total clinical efficacy, improvement of TCM syndrome patterns, and disease activity compared to western medicine alone, with a favorable safety. And the adverse reactions are predominantly mild gastrointestinal or neurological symptoms. Average daily costs range from 1.12 to 39.00 yuan. However, economic research is insufficient. There is sufficient evidence showing that Shenling Baizhu San/Pills/Granules and Bupi Yichang Wan for spleen deficiency with Qi stagnation, as well as Guchang Zhixie Wan/Capsules for liver depression with spleen deficiency pattern have notable advantages in efficacy, safety, and recurrence rate reduction. Nevertheless, the methodological quality of current research is generally low, with substantial heterogeneity in outcome indicators, and lack of long-term follow-up and real-world evidence. High-quality clinical research, pharmacoeconomic evaluations are urgently needed to support decision-making and rational drug use.